Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13 Pancreatic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Sarcoma, Ewing 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Kidney Neoplasms 1 Hepatoblastoma 1 Fanconi Anemia, Complementation Group D1 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Adenocarcinoma 1

Interventions

pembrolizumab 92 Gemcitabine 56 Nivolumab 50 Cisplatin 39 atezolizumab 37 Carboplatin 30 avelumab 29 enfortumab vedotin 26 Docetaxel 23 Magnetic Resonance Spectroscopy 19 Mitomycin 17 Ipilimumab 17 Paclitaxel 16 Specimen Handling 14 durvalumab 11 toripalimab 10 sacituzumab govitecan 10 Pemetrexed 10 cabozantinib 9 Taxes 8 vinflunine 7 Cyclophosphamide 7 tislelizumab 6 Injections 6 Bevacizumab 6 pemigatinib 5 fludarabine 5 disitamab vedotin 5 Standard of Care 5 Radiosurgery 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × talazoparib × Genitourinary × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡